Behavioural pharmacology of glutamate receptors in the basal ganglia

Neuroscience and Biobehavioral Reviews

Volumn 21, Issue 4, 1997, Pages 381-392

  Schmidt, Werner J ^a   Kretschmer, Beate D ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

AMPA; Basal ganglia; Catalepsy stereotypy; Glutamate receptors; Glycine site; Locomotion; Metabotropic behaviour; Neurochemistry; NMDA; Parkinson's disease

Indexed keywords

ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; AMPA RECEPTOR ANTAGONIST; GLUTAMATE RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

ARTICLE; BASAL GANGLION; BEHAVIOR; CATALEPSY; DOPAMINE RELEASE; DRUG EFFECT; LOCOMOTION; NEUROCHEMISTRY; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; STEREOTYPY;

ANIMALS; BASAL GANGLIA; BEHAVIOR; BEHAVIOR, ANIMAL; HUMANS; RECEPTORS, GLUTAMATE;

EID: 0030983284     PISSN: 01497634     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0149-7634(96)00044-9     Document Type: Article

References (142)

1. 1. Albin, R. L.; Makowiec, R. L.; Hollingsworth, Z. R.; Dure IV, L. S.; Penny, J. B.; Young, A. B., Excitatory amino acid binding sites in the basal ganglia of the rat: quantitative autoradiographic study. Neuroscience, 46, 135-148 1992.
2. 2. Alkhatib, I.; Karadag, H. C.; Ulugol, A., The behavioral effects of MK-801 injected into nucleus accumbens and caudate-putamen of rats. Pharmacol. Biochem. Behav., 52, 723-730 1995.
3. 3. Benazzouz, A.; Boraud, T.; Dubedat, P.; Boireau, A.; Stutzmann, J. M.; Gross, C., Riluzole prevents MPTP-induced parkinsonism in the rhesus monkey: a pilot study. Eur. J. Pharmacol., 284, 299-307 1995.
4. 4. Bennett, D. A.; Bernard, P. S.; Amrick, C. L.; Wilson, D. E.; Liebman, J. M.; Hutchinson, A. J., Behavioral pharmacological profile of CGS 19755, a competitive antagonist at N-methyl-D-aspartate receptors. J. Pharmacol. Exp. Ther., 250, 454 1989.
5. 5. Bigge, C. F., Structural requirements for the development of potent N-methyl-D-aspartic acid (NMDA) receptor antagonists. Biochem. Pharmacol., 45, 1547-1561 1993.
6. 6. Boldry, R. C.; Kelland, M. D.; Engber, T. M.; Chase, T. N., NBQX inhibits AMPA-induced locomotion after injection into the nucleus accumbens. Brain Res., 600, 331-334 1993.
7. 7. Boldry, R. C.; Layer, R. T.; Wallace, L. J.; Uretsky, N. J., Stimulation of locomotor activity by intra-accumbens AMPA is not inhibited by neonatal 6-hydroxydopamine-induced lesions. Neurosci. Lett., 138, 265-269 1992.
8. 8. Boldry, R. C.; Willins, D. L.; Wallace, L. J.; Uretsky, N. J., The role of endogenous dopamine in the hypermotility response to intra-accumbens AMPA. Brain Res., 559, 100-108 1991.
9. 9. Bristow, L. J.; Hutson, P. H.; Thorn, L.; Tricklebank, M. D., The glycine/NMDA receptor antagonist, R-( + )-HA-966, blocks activation of the mesolimbic dopamine system induced by phencyclidine and dizocilpine (MK-801) in rodents. Br. J. Pharmacol., 108, 1156-1163 1993.
10. 10. Bubser, M.; Keseberg, U.; Notz, P. K.; Schmidt, W. J., Differential behavioural and neurochemical effects of competitive and non-competitive NMDA receptor antagonists in rats. Eur. J. Pharmacol., 229, 75-82 1992.
11. 11. Bubser, M.; Tzschentke, T.; Hauber, W., Behavioural and neurochemical interactions of the AMPA antagonist GYKI 52466 and the non-competitive NMDA antagonist dizocilpine in rats. J. Neural. Transm., 101, 115-126 1995.
12. 12. Bubser, M.; Zadow, B.; Rückert, N. G. H.; Keseberg, U.; Kronthaler, U.; Schmidt, W. J., Behavioural actions of the non-competitive NMDA antagonists dextrorphan and ADCI in relation to dopaminergic mechanisms. Behav. Pharmacol., 5 (S1), 177 1994.
13. 13. Burns, L. H.; Everitt, B. J.; Kelley, A. E.; Robbins, T. W., Glutamate-dopamine interaction in the ventral striatum: role in locomotor activity and responding with conditioned reinforcement. Psychopharmacology, 115, 516-528 1994.
14. 14. Calderon, S. F.; Sanberg, P. R.; Norman, A. B., Quinolinic acid lesions of rat striatum abolish D1- and D2- dopamine receptor-mediated catalepsy. Brain Res., 450, 403-407 1988.
15. 15. Campbell, K.; Björklund, A., Prefrontal corticostriatal afferents maintain increased enkephalin gene expression in the dopamine-denervated rat striatum. Eur. J. Neurosci., 6, 1371-1383 1994.
16. 16. Carlsson, M.; Carlsson, A., The NMDA antagonist MK 801 causes marked locomotor stimulation in monoamine-depleted mice. J. Neural Transm., 75, 221-226 1989.
17. 17. Carlsson, M.; Carlsson, A., Dramatic synergism between MK-801 and clonidine with respect to locomotor stimulatory effect in monoamine-depleted mice. J. Neural Transm., 77, 65-71 1989.
18. 18. Carlsson, M.; Svensson, A., Interfering with glutamatergic neurotransmission by means of NMDA antagonist administration discloses the locomotor stimulatory potential of other transmitter systems. Pharmacol. Biochem. Behav., 36, 45-50 1990.
19. 19. Carlsson, M.; Svensson, A., The non-competitive NMDA antagonists MK-801 and PCP, as well as the competitive NMDA antagonist SDZ EAA494 (D-CPPene), interact synergistically with clonidine to promote locomotion in monoamine-depleted mice. Life Sci., 47, 1729-1736 1990.
20. 20. Carroll, C. B.; Holloway, V.; Brotchie, J. M.; Mitchell, I. J., Neurochemical and behavioral investigations of the NMDA receptor-associated glycine site in the rat striatum: functional implications for the treatment of parkinsonian symptoms. Psychopharmacology, 119, 55-65 1995.
21. 21. Castro-Alamancos, M. A.; Borell, J., Motor acitivity induced by disinhibiton of the primary motor cortex of the rat is blocked by a non-NMDA glutamate receptor antagonist. Neurosci Lett., 150, 183-186 1993.
22. 22. Christoffersen, C. L.; Meltzer, L. T., Evidence for N-methyl-D-aspartate and AMPA subtypes of the glutamate receptor on substantia nigra dopamine neurons: possible preferential role for N-methyl-D-aspartate receptors. Neuroscience, 67, 373-381 1995.
23. 23. Clineschmidt, B. V.; Martin, G. E.; Bunting, P. R., Anticonvulsant activity of ( + )-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine (MK-801), a substance with potent anticonvulsant, central sympathomimetic, and apparent anxiolytic properties. Drug Dev. Res., 2, 123-134 1982.
24. 24. Close, S. P.; Elliott, P. J.; Hayes, A. G.; Marriott, A. S., Effects of classical and novel agents in a MPTP-induced reversible model of Parkinson's disease. Psychopharmacology, 102, 295-300 1990.
25. 25. Colpaert, F. C., Pharmacological characteristics of tremor, rigidity and hypokinesia induced by reserpine in rat. Neuropharmacology, 26, 1431-1440 1987.
26. 26. Cools, A. R.; Peeters, B. W. M. M., Behavioral function of neostriatal glutamate and its interaction with dopamine. Neurosci. Res. Commun., 1, 47-55 1987.
27. 27. Creese, I.; Iversen, S. D., The pharmacological and anatomical substrates of the amphetamine response in the rat. Brain Res., 83, 419-436 1975.
28. 28. Dall'Olio, R.; Rimondini, R.; Gandolfi, O., The competitive NMDA antagonists CGP 43487 and APV poteniate dopaminergic function. Psychopharmacology, 118, 310-315 1995.
29. 29. Danysz, W.; Essman, U.; Bresink, I.; Wilke, R., Glutamate antagonists have different effects on spontaneous locomotor activity in rats. Pharmacol. Biochem. Behav., 48, 111-118 1994.
30. 30. Dawbarn, D.; Pycock, C. J., Motor effects following application of putative excitatory amino acid antagonists to the region of the mesencephalic dopamine cell bodies in the rat. Naunyn-Schmiede-berger's Arch. Pharmacol., 318, 100-104 1981.
31. 31. Donevan, S. D.; Rogawski, M. A., GYKI 52466, a 2,3-benzodiazepine, is a highly selective, noncompetitive antagonist of AMPA/ kainate receptor responses. Neuron, 10, 51-59 1993.
32. 32. Donzanti, B. A.; Uretsky, N. J., Antagonism of the hypermotility response induced by excitatory amino acids in the rat nucleus accumbens. Naunyn-Schmiedeberger's Arch. Pharmacol., 325, 1-7 1984.
33. 33. Ellenbroek, B.; Schwarz, M.; Sontag, K. H.; Jaspers, R.; Cools, A., Muscular rigidity and delineation of a dopamine-specific neostriatal subregion: tonic EMG activity in rats. Brain Res., 345, 132-140 1985.
34. 34. Elliott, P. J.; Close, S. P.; Walsh, D. M.; Hayes, A. G.; Marriott, A. S., Neuroleptic-induced catalepsy as a model of Parkinson's disease II. Effect of glutamate antagonists. J. Neural Transm., 2, 91-100 1990.
35. 35. Fadda, E. W.; Danysz, W., Glycine and D-serine increase the affinity of N-methyl-D-aspartate sensitive glutamate binding sites in rat brain synaptic membranes. Neuropharmacology, 27, 1183-1185 1988.
36. 36. Forsythe, I. D.; Clements, J. D., Presynaptic glutamate receptors depress excitatory monsynaptic transmission between mouse hippocampal neurons. J. Physiol. (London), 429, 1-16 1990.
37. 37. Foster, A. C. The molecular pharmacology of excitatory amino acid receptors. J. Psychopharmacology Abstract Book BAP/EBPS Meeting 1992 A37, 1992.
38. 38. Fredriksson, A.; Gentsch, C.; Archer, T., Synergistic interaction between NMDA-antagonists and L-Dopa on activity in MPTP-treated mice. J. Neural Transm., 97, 197-209 1994.
39. 39. Freeman, A. S.; Bunney, B. S., The effects of phenyclidine and N-allylnormetazocine on midbrain dopamine neuronal activity. Eur. J. Pharmacol., 104, 287-293 1984.
40. 40. French, E. D., Effects of phencyclidine on ventral tegmental A10 dopamine neurons in the rat. Neuropharmacology, 25, 241-248 1986.
41. 41. French, E. D., Competitive NMDA receptor antagonists attenuate phencyclidine-induced excitations of A10 dopamine neurons. Eur. J. Pharmacol., 271, 1-7 1992.
42. 42. French, E. D.; Ceci, A., Non-competitive N-methyl-D-aspartate antagonists are potent activatiors of ventral tegmental A10 dopamine neurons. Neurosci. Lett., 119, 159-162 1990.
43. 43. French, E. D.; Ferkany, J.; Abreu, M.; Levenson, S., Effects of competitive N-methyl-D-aspartate antagonists on midbrain dopamine neurons: an electrophysiological and behavioral comparison to phencyclidine. Neuropharmacology, 30, 1039-1046 1991.
44. 44. French, E. D.; Mura, A.; Wang, T., MK-801, phencyclidine (PCP), and PCP-like drugs increase burst firing in rat A10 dopamine neurons: comparision to competitive antagonists. Synapse, 13, 108-116 1993.
45. 45. Goodwin, P.; Starr, B. S.; Starr, M. S., Motor responses to dopamine D1 and D2 agonists in the reserpine-treated mouse are affected differentially by the NMDA recptor antagonist MK 801. J. Neural Trans., 4, 15-26 1992.
46. 46. Gossel, M.; Schmidt, W. J.; Löscher, W.; Zajaczkowski, W.; Danysz, W., Effect of coadministration of glutamate receptor antagonists and dopaminergic agonists on locomotion in monoamine-depleted rats. J. Neural Transm., 10, 27-39 1995.
47. 47. Graham, W. C.; Robertson, R. G.; Sambrook, M. A.; Crossman, A. R., Injection of excitatory amino acid antagonists into the medial pallidal segment of a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treated primate reverses motor symptoms of Parkinsonism. Life Sci., 47, 91-97 1990.
48. 48. Hauber, W.; Andersen, R., The non-NMDA glutamate receptor antagonist GYKI 52466 counteracts locomotor stimulation and anticataleptic activity induced by the NMDA antagonist dizocilpine. Naunyn-Schmiedeberg's Arch. Pharmacol., 348, 486-490 1993.
49. 49. Hauber, W.; Schmidt, W. J., The NMDA antagonist dizocilpine (MK-801) reverses haloperidol-induced movement initiation deficits. Behav. Brain Res., 41, 161-166 1990.
50. 50. Hauber, W.; Schmidt, W. J., Discrete quinolinic acid lesions of the lateral but not of the medial caudate-putamen reversed haloperidol-induced catalepsy in rats. J. Neural Transm., 94, 103-114 1993.
51. 51. Hooks, M. S.; Kalivas, P. W., Involvement of dopamine and excitatory amino acid transmission in novelty-induced motor actitivty. J. Pharmacol. Exp. Ther., 269, 976-988 1994.
52. 52. Hutson, P. H.; Bristow, L. J.; Thorn, L.; Tricklebank, M. D., R-( + )-HA-966, a glycine/NMDA receptor antagonist, selectively blocks the activation of the mesolimbic dopamine system by amphetamine. Br. J. Pharmacol., 103, 2037-2044 1991.
53. 53. Imperato, A.; Honore, T.; Jensen, L. H., Dopamine release in the nucleus caudatus and in the nucleus accumbens is under glutamatergic control through non-NMDA receptors: a study in freely-moving rats. Brain Res., 530, 223-228 1990.
54. 54. Imperato, A.; Scrocco, M. G.; Bacchi, S.; Angelucci, L., NMDA receptors and in vivo dopamine release in the nucleus accumbens and caudatus. Eur. J. Pharmacol., 187, 555-556 1990.
55. 55. Iversen, S. D.; Wilkinson, S.; Simpson, B., Enhanced amphetamine responses after frontal cortex lesions in the rat. Eur. J. Pharmacol., 13, 387-390 1971.
56. 56. Johnson, J. W.; Ascher, P., Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature, 325, 529-531 1987.
57. 57. Kannari, K.; Markstein, R., Dopamine agonists potentiate antiakinetic effects of competitive NMDA antagonists in monoamine-depleted mice. J. Neural Transm., 84, 211-220 1991.
58. 58. Keefe, K. A.; Zigmond, M. J.; Abercrombie, E. D., In vivo regulation of extracellular dopamine in the neostriatum: influence of impulse activity and local excitatory amino acids. J. Neural Transm., 91, 223-240 1993.
59. 59. Kelley, A. E.; Maldonado-Irizarry, C. S., On the behavioral role of excitatory amino acids in the nucleus accumbens: studies of core and shell subregions. Behav. Pharmacol., 6, 622 1995.
60. 60. Kelley, A. E.; Throne, L. C., NMDA receptors mediate the behavioral effects of amphetamine infused into the nucleus accumbens. Brain Res. Bull., 29, 247-254 1992.
61. 61. Kiss, J. P.; Toth, E.; Lajtha, A.; Vizi, E. S., NMDA receptors are not involved in the MK-801-induced increase of striatal dopamine release in rat: a mircodialysis study. Brain Res., 641, 145-148 1994.
62. 62. Kleckner, N. W.; Dingledine, R., Requirement for glycine in activation of NMDA-receptors expressed in Xenopus oocytes. Science, 241, 835-837 1988.
63. 63. Klockgether, T.; Turski, L., NMDA antagonists potentiate antiparkinsonian actions of L-dopa in monoamine-depleted rats. Ann. Neurol., 28, 539-546 1990.
64. 64. Klockgether, T.; Turski, L., Toward an understanding of the role of glutamate in experimental Parkinsonism: agonist-sensitive sites in the basal ganglia. Ann. Neurol., 34, 585-593 1993.
65. 65. Koek, W.; Colpaert, F. C., Selective blockade of N-methyl-D-aspartate (NMDA)-induced convulsions by NMDA antagonists and putative glycine antagonists: relationship with phencyclidine-like behavioral effects. J. Pharmacol. Exp. Ther., 252, 349-357 1990.
66. 66. Kretschmer, B. D., Felbamate, an anti-convulsive drug, has antiparkinsonian potential in rats. Neurosci. Lett., 179, 115-118 1994.
67. 67. Kretschmer, B. D.; Bubser, M.; Schmidt, W. J., Behavioral and neurochemical actions of the strychnine-insensitive glycine receptor antagonist, 7-chlorokynurenate, in rats. Eur. J. Pharmacol., 280, 37-45 1995.
68. 68. Kretschmer, B. D.; Schmidt, W. J. Behavioral effects mediated by the modulatory glycine site of the NMDA receptor in the anterodorsal striatum and nucleus accumbens. J. Neurosci., 16, 1561-1568 1996.
69. 69. Kretschmer, B. D.; Winterscheid, B.; Danysz, W.; Schmidt, W. J., Glycine site antagonists abolish dopamine D2 but not D1 receptor mediated catalepsy in rats. J. Neural Transm., 95, 123-136 1994.
70. 70. Kretschmer, B. D.; Zadow, B.; Volz, T. L.; Volz, L.; Schmidt, W. J., The contribution of the different binding sites of the N-methyl-D-aspartate (NMDA) receptor to the expression of behavior. J. Neural Transm., 87, 23-35 1992.
71. 71. Kronthaler, U. O.; Bubser, M.; Schmidt, W. J., Striatal 6-OHDA lesions and sensorimotor functions in rats. Behav. Pharmacol., 5 (S1), 117 1994.
72. 72. Kronthaler, U. O.; Bubser, M.; Schmidt, W. J., MK-801 mediates locomotion via dopaminergic neurons. Behav. Pharmacol., 6, 623 1995.
73. 73. Kronthaler, U. O.; Schmidt, W. J. 1S,3R-ACPD has cataleptogenic effects and reverses MK-801- and less pronounced, D,L-amphetamine-induced locomotion. Eur. J. Pharmacol., 316, 129-136 1996.
74. 74. LaLonde, R.; Cote, C., Behavioral effects of non-NMDA glutamate receptor antagonists. Neurosci. Biobehav. Rev., 17, 79-84 1993.
75. 75. Löscher, W.; Annies, R.; Hönack, D., Comparison of competitive and uncompetitive NMDA receptor antagonists with regard to monoaminergic neuronal activity and behavioral effects in rats. Eur. J. Pharmacol., 242, 263-274 1993.
76. 76. Löschmann, P. A.; Lange, K. E.; Kunow, M.; Rettig, K. J.; Honore, T.; Turski, L.; Wachtel, H.; Jenner, P.; Marsden, C. D., Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with L-Dopa in models of Parkinson's disease. J. Neural Transm., 3, 203-213 1991.
77. 77. Luquin, M. R.; Obeso, J. A.; Laguna, J.; Guillen, J.; Martinez-Lage, J. M., The AMPA receptor antagonist NBQX does not alter the motor response induced by selective dopamine agonists in MPTP-treated monkeys. Eur. J. Pharmacol., 235, 297-300 1993.
78. 78. Maj, J.; Skuza, G.; Rogoz, Z., Some central effects of CGP 37849 and CGP 39551, the competitive NMDA receptor antagonists: potential antiparkinsionan activity. J. Neural Transm., 6, 53-62 1993.
79. 79. Maj, J.; Sowinska, H.; Baran, L.; Sarnek, J., Pharmacological effects of 1,3-dimethyl-5-aminoadamantane, a new adamantane derivate. Eur. J. Pharmacol., 26, 9-14 1974.
80. 80. Maldonado-Irizary, C. S.; Kelley, A. E., Differential behavioral effects following microinjection of an NMDA antagonist into nucleus accumbens subregions. Psychopharmacology, 116, 65-72 1994.
81. 81. Martinez-Fong, D.; Resales, M. G.; Gongora-Alfaro, J. L.; Hernandez, S.; Aceves, J., NMDA receptor mediates dopamine release in the striatum of unanesthetized rats as measured by brain mircodialysis. Brain Res., 595, 309-315 1992.
82. 82. McCullough, L. D.; Salamone, J. D., Increase in extracellular dopamine levels and locomotor activity after direct infusion of phencyclidine into the nucleus accumbens. Brain Res., 577, 1-9 1992.
83. 83. McMillen, B. A.; Williams, H. L.; Lehmann, H.; Shepard, P. D., On central muscle relaxants, strychnine-insensitive glycine receptors and two old drugs: zoxazolamine and HA-966. J. Neural Trans., 89, 11-25 1992.
84. 84. Mehta, A. K.; Ticku, M. K., Role of N-methyl-D-aspartate (NMDA) receptors in experimental catalepsy in rats. Life Sci., 46, 37-42 1990.
85. 85. Mitchell, I. J.; Hughes, N.; Caroll, C. B.; Brotchie, J. M., Reversal of parkinsonian symptoms by intrastriatal and systemic manipulations of excitatory amino acid and dopamine transmission in the bilateral 6-OHDA lesioned marmoset. Behav. Pharmacol., 6, 492-507 1995.
86. 86. Moghaddam, B.; Gruen, R. J.; Roth, R. H.; Bunney, B. S.; Adams, R. N., Effect of L-glutamate on the release of striatal dopamine: in vivo dialysis and electrochemical studies. Brain Res., 518, 55-60 1990.
87. 87. Moore, N. A.; Blackman, A.; Awere, S.; Leander, J. J. D., NMDA receptor antagonists inhibit catalepsy induced by either dopamine D1 or D2 receptor antagonists. Eur. J. Pharmacol., 237, 1-7 1993.
88. 88. Mos, J.; Broxterman, H. J.; Bennekom, W. P., In vivo voltammetric investigation into the action of HA-966 on central dopaminergic neurons. Brain Res., 207, 465-470 1981.
89. 89. Murase, S.; Grenhoff, J.; Chouvet, G.; Gonon, F. G.; Svensson, T. H., Prefrontal cortex regulates burst firing and transmitter release in rat mesolimbic dopamine neurons studied in vivo. Neurosci. Lett., 157, 53-56 1993.
90. 90. O'Neill, K. A.; Carelli, R. M.; Jarvis, M. F.; Liebman, J. M., Hyperactivity induced by N-methyl-D-aspartate injections into nucleus accumbens: lack of evidence for mediation by dopaminergic neurons. Pharmacol. Biochem. Behav., 34, 739-745 1989.
91. 91. Ossowska, K.; Karcz, M.; Wardas, J.; Wolfarth, S., Striatal and nucleus accumbens D1/D2 dopamine receptors in neuroleptic catalepsy. Eur. J. Pharmacol., 182, 327-334 1990.
92. 92. Overton, P.; Clark, D., Iontophoretically adminstered drugs acting at the N-methyl-D-aspartate receptor modulate burst firing in A9 dopamine neurons in the rat. Synapse, 10, 131-140 1992.
93. 93. Papa, S. M.; Engber, T. M.; Boldry, R. C.; Chase, T. N., Opposite effects of NMDA and AMPA receptor blockade on catalepsy induced by dopamine receptor antagonists. Eur. J. Pharmacol., 232, 247-253 1993.
94. 94. Parada-Turska, J.; Turski, W. A., Excitatory amino acid antagonists and memory: effect of drugs acting at N-methyl-D-aspartate receptors in learning and memory tasks. Neuropharmacology, 29, 1111-1116 1990.
95. 95. Pierce, R. C.; Rebec, G. V., Intraneostriatal administration of glutamate antagonists increases behavioral activation and decreases neostriatal ascorbate via nondopaminergic mechanisms. J. Neurosci., 13, 4272-4280 1993.
96. 96. Raffa, R. B.; Ortegon, M. E.; Robisch, D. M.; Martin, G. E., In vivo demonstration of the enhancement of MK-801 by L-glutamate. Life Sci., 44, 1593-1599 1989.
97. 97. Rao, T. S.; Contreras, P. C.; Wood, P. L., Are N-methyl-D-aspartate (NMDA) and phencyclidine (PCP) receptors always functionally coupled to each other? Neurochem. Int., 17, 1-8 1990.
98. 98. Rao, T. S.; Cler, J. A.; Mick, S. J.; Emmett, M. R.; Farah, J. M.; Contreras, P. C.; Iyengar, S.; Wood, P. L., Neurochemical interaction of competitive N-methyl-D-aspartate antagonists with dopaminergic neurotransmission and the cerebellar cyclic GMP system: functional evidence for a phasic glutamateric control of the nigrostriatal dopaminergic pathway. J. Neurochem., 56, 907-913 1991.
99. 99. Rao, T. S.; Kim, H. S.; Lehmann, J.; Martin, L. L.; Wood, P. L., Interactions of phencyclidine receptor agonist MK-801 with dopaminergic system: regional studies in the rat. J. Neurochem., 54, 1157-1162 1990.
100. 100. Ross, R. T., Drug-induced Parkinsonism and other movement disorders. Can. J. Neurol. Sci., 17, 155-162 1990.
101. 101. Rückert, N. G. H.; Schmidt, W. J., The receptor a ligand 1,3-di-(2-tolyl)guanidine in animal models of schizophrenia. Eur. J. Pharmacol., 233, 261-267 1993.
102. 102. Sacaan, A. I.; Monn, J. A.; Schoepp, D. D., Intrastriatal injection of a selective metabotropic excitatory amino acid receptor antagonist induces contralateral turning in the rat. J. Pharmacol. Exp. Ther., 259, 1366-1370 1991.
103. 103. Saccan, A. I.; Bymaster, F. P.; Schoepp, D. D., Metabotropic glutamate receptor activation produces extrapyramidal motor system activation that is mediated by striatal dopamine. J. Neurochem., 59, 245-251 1992.
104. 3H]MK-801 binding in rat brain. J. Neurochem., 60, 1344-1353 1993.
105. 105. Sanberg, P. R.; Bunsey, M. D.; Giordano, M.; Norman, A. B., The catalepsy test: its ups and downs. Behav. Neurosci., 102, 748-759 1988.
106. 106. Scatton, B.; Worms, P.; Lloyd, K. G.; Bartholini, G., Cortical modulation of striatal function. Brain Res., 232, 331-343 1982.
107. 107. Schmidt, W. J., Intrastriatal injection of DL-2-amino-5-phosphonovaleric acid (AP-5) induces sniffing stereotypy that is antagonized by haloperidol and clozapine. Psychopharmacology, 90, 123-130 1986.
108. 108. Schmidt, W. J.; Bubser, M., Anticataleptic effects of the N-methyl-D-aspartate antagonist MK-801 in rats. Pharmacol. Biochem. Behav., 32, 621-623 1989.
109. 109. Schmidt, W. J.; Bubser, M.; Hauber, W., Anticataleptic effects of NMDA receptor antagonists. Eur. J. Neurosci., S3, 118 1990.
110. 110. Schmidt, W. J.; Bubser, M.; Hauber, W., Behaviroural pharmacology of glutamate in basal ganglia. J. Neural Transm., S38, 65-89 1992.
111. 111. Schmidt, W. J.; Bury, D., Behavioural effects of N-methyl-D-aspartate in the anterodorsal striatum in the rat. Life Sci., 43, 545-549 1988.
112. 112. Schmidt, W. J.; Bury, D.; Geltz, U. Dopamine-glutamate interactions in the basal ganglia. In: Dopamine'92 - from neurobiology to neuropathology. Abstract book: 1992, 90. Univ. Di Cagliari Dipt. Neuroscienze..
113. 113. Schmidt, W. J.; Zadow, B.; Kretschmer, B. D.; Hauber, W., Anticataleptic potencies of glutamate-antagonists. Amino Acids, 1, 225-237 1991.
114. 114. Schoepp, D. D.; Conn, P. J., Metabotropic glutamate receptors in brain function and pathology. Trends Pharmacol. Sci., 14, 13-20 1993.
115. 115. Seeburg, P. H., The TINS/TiPS lecture - the molecular biology of mammalian glutamate receptor channels. Trend Neurosci., 16, 359-365 1993.
116. 116. Sladeczek, F.; Pin, J. P.; Recasens, M.; Blockaert, J.; Weiss, S., Glutamate stimulates inositol phosphate formation in striatal neurones. Nature, 317, 717-719 1985.
117. 117. Sorrels, T. L.; Bostock, E., Induction of feeding by 7-chlorokynurenic acid, a strychnine-insensitive glycine binding site antagonist. Brain Res., 572, 265-268 1992.
118. 118. Staton, D. M.; Solomon, P. R., Microinjection of D-amphetamine into the nucleus accumbens and caudatus putamen differentially affect stereotypy and locomotion in the rat. Physiol. Psychol., 12, 159-162 1984.
119. 119. Stephens, D. N., Behavioural pharmacology of AMPA antagonists. Behav. Pharmacol., 6, 633 1995.
120. 120. Svensson, A.; Pileblad, E.; Carlsson, M., A comparision between the non-competitive NMDA antagonist dizocilpine (MK-801) and the competitive NMDA antagonist D-CPPene with regard to dopamine turnover and locomotor-stimulatory properties in mice. J. Neural Transm., 85, 117-159 1991.
121. 121. Svensson, L.; Zhang, J.; Johannessen, K.; Engel, J. A., Effect of local infusion of glutamate analogue into the nucleus accumbens of rats: an electrochemical and behavioral study. Brain Res., 643, 155-161 1994.
122. 122. Tanabe, Y.; Nomura, A.; Masu, M.; Shigemoto, R.; Mizuno, N.; Nakanishi, S., Signal transduction, pharmacological properties, and expression pattern of two rat metabotropic glutamate receptors, mGLUR 3 and mGLUR 4. J. Neurosci., 13, 1372-1378 1993.
123. 123. Tiedtke, P. I.; Bischoff, C.; Schmidt, W. J., MK-801-induced stereotypy and its antagonism by neuroleptic drugs. J. Neural Transm., 81, 173-182 1990.
124. 124. Tricklebank, M. D.; Bristow, L. J.; Foster, A. C.; Hill, R. G.; Hutson, P. H.; Grimwood, S.; Kemp, J. A.; Kulagowski, J.; Leeson, P. D.; Marshall, G.; Mawer, I. M.; Priestley, T.; Rowley, M.; Saywell, K., The behavioural profile of the glycine/NMDA receptor antagonists, L-695,902 and L-701,324. Behav. Pharmacol., 5 (S1), 44 1994.
125. 125. Verma, A.; Kulkarni, S. K., D1/D2 dopamine and N-methyl-D-aspartate (NMDA) receptor participation in experimantal catalepsy in rats. Psychopharmacology, 109, 477-483 1992.
126. 126. Wachtel, H., Antiparkinsonian dopamine agonists: a review of the pharmacokinetics and neuropharmacology in animal and humans. J. Neural Transm., 3, 151-201 1991.
127. 127. Watkins, J. C.; Krogsgaard-Larsen, P.; Honore, T., Structure-activity relationships in the development of excitatory amino acid receptor agonists and competitive antagonists. Trends Pharmacol. Sci., 11, 25-33 1990.
128. 128. Wedzony, K.; Golembiowska, K.; Maj, J., A search for the effects of NMDA on the release of dopamine from the rat nucleus caudatus. In: Rollema, H.; Westerink, B. H. C.; Drijhout, W. J., eds. Monitoring molecules in neuroscience. Groningen: University Centre for Pharmacy; 1991:321-324.
129. 129. Wedzony, K.; Klimek, V.; Golembiowska, K., MK-801 elevates the extracellular concentration of dopamine in the rat prefrontal cortex and increases the density of striatal dopamine D1 receptors. Brain Res., 622, 325-329 1993.
130. 130. Weissenborn, R.; Winn, P., Regulatory behaviour, exploration and locomotion following NMDA or 6-OHDA lesions in the rat nucleus accumbens. Behav. Brain Res., 51, 127-137 1992.
131. 131. Westerink, B. H. C.; Santiago, M.; DeVries, J. B., The release of dopamine from nerve terminals and dendrites of nigrostriatal neurons induced by excitatory amino acids in the conscious rat. Naunyn-Schmiedeberger's Arch. Pharmacol., 345, 523-529 1992.
132. 132. Wroblewski, J. T.; Danysz, W., Modulation of glutamate receptors - molecular mechanism and functional implications. A. Rev. Pharmacol. Toxicol., 29, 441-474 1989.
133. 133. Wüllner, U.; Kupsch, A.; Arnold, G.; Renner, P.; Scheid, R.; Oertel, W.; Klockgether, T., The competitive NMDA antagonist CGP40.116 enhances L-DOPA response in MPTP-treated marmosets. Neuropharmacology, 31, 713-715 1992.
134. 134. Wüllner, U.; Standaert, D. G.; Testa, C. M.; Landwehrmeyer, B.; Catania, M. V.; Penny, J. B.; Young, A. B., Glutamate receptor expression in rat striatum: effect of deafferentation. Brain Res., 647, 209-219 1994.
135. 135. Wüllner, U.; Testa, C. M.; Catania, M. V.; Young, A. B.; Penny, J. B., Glutamate receptors in striatum and substantia nigra: effects of medial forebrain bundle lesions. Brain Res., 645, 96-102 1994.
136. 136. Yoshida, Y.; Ono, T.; Kawano, K.; Miyagishi, T., Distinct sites of dopaminergic and glutamatergic regulation of haloperidol-induced catalepsy within the rat caudate-putamen. Brain Res., 639, 139-148 1994.
137. 137. Yoshida, Y.; Ono, T.; Kizu, A.; Fukushima, R.; Miyagishi, T., Striatal N-methyl-D-aspartate receptors in haloperidol-induced catalepsy. Eur. J. Pharmacol., 203, 173-180 1991.
138. 138. Yougren, K. D.; Daly, D. A.; Moghaddam, B., Distinct actions of endogenous excitatory amino acids on the outflow of dopamine in the nucleus accumbens. J. Pharmacol. Exp. Ther., 264, 289-293 1993.
139. 139. Zadow, B.; Bubser, M.; Schmidt, W. J., Quinolinic acid-induced lesion of the substantia nigra pars reticulata: behavioural and neurochemical effects. Soc. Neurosci. Abstr., 20, 1365 1994.
140. 140. Zadow, B.; Schmidt, W. J., Lesions of the entopeduncular neucleus and the subthalamic nucleus reduce dopamine antagonist-induced catalepsy in rat. Behav. Brain. Res., 62, 71-79 1994.
141. 141. Zadow, B.; Schmidt, W. J., The AMPA antagonists NBQX and GYKI 52466 do not counteract neuroleptic-induced catalepsy. Naunyn-Schmiedeberg's Arch. Pharmacol., 349, 61-65 1994.
142. 142. Zhang, J.; Chiodo, L. A.; Freeman, A. S., Electrophysiological effects of MK-801 on rat nigrostriatal and mesoaccumbal dopaminergic neurons. Brain Res., 590, 153-163 1992.